Table 2.
Pt | Diagnosis | Positive markers | Negative markers |
---|---|---|---|
3 | Chromophobe RCC | CK7, PAX8, CD10 (cytoplasmic), RCC (rare cells) | ER, calretinin, inhibin, vimentin |
4 | Clear cell RCC | EMA | CK7, CK20 |
5a | RCC, unclassified | PAX8, vimentin, P504S, p53, CK20 (focal) | CK7, WT-1, PIN dual (HMWK and p63), cytokeratin 5/6, CD10, ER |
8 | Clear cell RCC | Vimentin, LMWK | HMWK |
Abbreviations: CK7 indicates cytokeratin 7; ER, estrogen receptor; EMA, epithelial membrane antigen; CK20, cytokeratin 20; P504S, alpha-methylacyl CoA racemase; HMWK, high-molecular-weight keratin; LMWK, low-molecular-weight keratin.
In patient 5, immunohistochemical staining was performed on both primary kidney tumor (positive for pancytokeratin AE1/AE3, E-cadherin, vimentin, CK20, CD10, CD117, P504S, and carbonic anhydrase. The tumor cells were negative for CK7, thrombomodulin, actin, HMB-45, cytokeratin 5/6, WT-1, P63, and Melan-A), as well as abdominal wall masses (as shown in the table). The primary and metastatic tumors (including the ovarian tumor) showed similar morphology, and this case was diagnosed as RCC, unclassified.